Dr. Jared Weiss is the Section Chief of Thoracic and Head/Neck Oncology and a Professor of Medicine at the UNC School of Medicine and the UNC Lineberger Comprehensive Cancer Center. He specializes in lung cancer, squamous head and neck cancer, and other cancers including malignant pleural mesothelioma with a focus on the use of immunotherapy,
Dr. Chad Pecot is a thoracic medical oncologist at UNC Health and Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina. He specializes in lung cancer and abnormal tumors inside the chest, including malignant pleural mesothelioma. He chose lung cancer as a specialty because of its lethality, and he is grateful that through research, patients
Dr. Carrie Lee is a thoracic oncologist at the University of North Carolina Health in Chapel Hill, a Professor at UNC School of Medicine, and Director of the Thoracic Oncology Program at UNC Lineberger Comprehensive Cancer Center. Her clinical practice focuses on lung cancer and she has broad experience with traditional chemotherapy protocols as well
A just-released study conducted in the Netherlands provides a mixed assessment of the use of nivolumab-ipilimumab immunotherapy in patients with malignant pleural mesothelioma. While researchers found that the real-world efficacy of the combination was comparable to what was reported in a phase 3 study, they also reported that toxicities – particularly among elderly patients –
Dr. William Petty is a medical oncologist and hematologist in the department of Medical Oncology at the Wake Forest Medical Center and Wake Forest Comprehensive Cancer Center. As Director of the Thoracic Oncology program, he specializes in treating patients diagnosed with lung cancer and malignant pleural mesothelioma. Dr. Petty’s philosophy on taking care of patients
A group of researchers from cancer centers in Vienna has announced that they’ve identified a therapeutic target that, when inhibited, enhances mesothelioma tumors’ sensitivity to chemotherapy and radiotherapy. The group believes that this approach may yield a novel and effective treatment approach for the rare, asbestos-related disease.
Dr. Clarke is a medical oncologist within Duke Health and the Duke Cancer Institute in Durham, North Carolina. He specializes in treating patients with cancers of the chest, including malignant mesothelioma and lung cancer. He says that the most rewarding part of his work is developing long-term relationships with his patients and their families throughout
Dr. Tong is an accomplished clinical surgeon at Duke Health and Duke Cancer Institute in Durham, North Carolina. Her focus is on thoracic oncology and minimally invasive thoracic surgery and her clinical expertise is in lung and esophageal cancer surgery as well as surgery for the treatment of malignant pleural mesothelioma. She has achieved international
One of the most challenging aspects of pursuing a mesothelioma or asbestos-related lung cancer lawsuit is the significant gap between when the victim’s exposure took place and when their illness is diagnosed. It’s hard for anybody to remember details from four or five decades earlier, and this is especially true when fighting a fatal disease.
Dr. Abraham Chachoua is the Director of the Lung Cancer Center at the Perlmutter Cancer Center of NYU Langone. In his role, he specializes in treating thoracic cancers including lung cancer and malignant pleural mesothelioma. A recognized leader in lung cancer therapy, Dr. Chachoua became interested in the field of medicine, particularly in oncology, after